The psychedelic medicine sector is undergoing a rapid and consequential transformation.
What was once considered to be an experimental, edgier corner of neuroscience is now evolving into a clinically validated and policy-supported therapeutic category with meaningful implications for biotechnology companies, investors, healthcare systems and, of course, patients.
For decades, neuropsychiatric drug development has been defined by incremental progress.
Although existing treatments for conditions such as generalised anxiety disorder (GAD), depression and related mental health disorders have helped many patients, a significant proportion continue to experience inadequate response or relapse.
In practice, clinicians often face a persistent gap between available therapies and the complexity of real-world disease burden. That gap is now beginning to narrow.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
